Want to see IN:GLAXO full AI Analyst Report?
GLAXO Stock Chart & Stats
₹2513.25
₹36.90(1.47%)
At close: 4:00 PM EDT
₹2513.25
₹36.90(1.47%)
Day’s Range― - ―
52-Week Range₹2,088.00 - ₹3,121.10
Previous CloseN/A
Volume67.92K
Average Volume (3M)17.72K
Market Cap
₹499.17B
Enterprise Value₹359.33K
Total Cash (Recent Filing)₹27.57B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)46.6
Beta0.72
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.94%
Share Statistics
EPS (TTM)63.05
Shares Outstanding169,406,040
10 Day Avg. Volume44,550
30 Day Avg. Volume17,722
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.65
Revenue Forecast (FY)₹42.48B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthThe return to consistent revenue growth indicates recovering demand and improving commercial execution. Sustained top-line expansion can support operating leverage and provide a durable base for earnings growth over the next several quarters.
Improving ProfitabilityHigher EBIT and net margins suggest improved operating leverage, product mix, or cost discipline. If maintained, stronger profitability should improve earnings resilience and provide more internal funding for product and commercial investment.
Conservative Balance Sheet And Strong Cash FlowMinimal leverage gives the company substantial financial flexibility and reduces balance-sheet risk. Free cash flow closely tracking earnings also indicates strong earnings quality, supporting dividends, investment, and resilience through operating fluctuations.
Bears Say
Volatile Operating Cash ConversionUneven operating cash conversion indicates working-capital swings or timing effects that can make cash generation less predictable than accounting earnings. This may complicate planning and reduce the consistency of funds available for investment or shareholder returns.
Balance-Sheet VolatilityAlthough leverage remains very low, the earlier contraction in equity and assets shows that the balance sheet has not been entirely stable. Continued monitoring is warranted because further asset or equity volatility could affect financial flexibility and reported returns.
Earnings Quality Risk From Profit VolatilityThe unusually high 2022 margin makes historical earnings comparisons less reliable and highlights profit volatility. Normalized performance is more representative, so future growth must come from repeatable operations rather than exceptional prior-period results.
GlaxoSmithKline Pharmaceuticals Limited News
GLAXO FAQ
What was GlaxoSmithKline Pharmaceuticals Limited’s price range in the past 12 months?
GlaxoSmithKline Pharmaceuticals Limited lowest stock price was ₹2088.00 and its highest was ₹3121.10 in the past 12 months.
What is GlaxoSmithKline Pharmaceuticals Limited’s market cap?
GlaxoSmithKline Pharmaceuticals Limited’s market cap is ₹499.17B.
When is GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date?
GlaxoSmithKline Pharmaceuticals Limited’s upcoming earnings report date is Nov 05, 2026 which is in 62 days.
How were GlaxoSmithKline Pharmaceuticals Limited’s earnings last quarter?
GlaxoSmithKline Pharmaceuticals Limited released its earnings results on Aug 03, 2026. The company reported ₹14 earnings per share for the quarter, beating the consensus estimate of ₹13.9 by ₹0.1.
Is GlaxoSmithKline Pharmaceuticals Limited overvalued?
According to Wall Street analysts GlaxoSmithKline Pharmaceuticals Limited’s price is currently Overvalued.
Does GlaxoSmithKline Pharmaceuticals Limited pay dividends?
GlaxoSmithKline Pharmaceuticals Limited pays a Annually dividend of ₹57 which represents an annual dividend yield of 1.94%. See more information on GlaxoSmithKline Pharmaceuticals Limited dividends here
What is GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate?
GlaxoSmithKline Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlaxoSmithKline Pharmaceuticals Limited have?
GlaxoSmithKline Pharmaceuticals Limited has 169,406,040 shares outstanding.
What happened to GlaxoSmithKline Pharmaceuticals Limited’s price movement after its last earnings report?
GlaxoSmithKline Pharmaceuticals Limited reported an EPS of ₹14 in its last earnings report, beating expectations of ₹13.9. Following the earnings report the stock price went up 0.141%.
Which hedge fund is a major shareholder of GlaxoSmithKline Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:GLAXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Gland Pharma Ltd.
―
PFIZER LIMITED
―
Sanofi Consumer Healthcare India Limited
―